Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Hematological Oncology|April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world dataFrancesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Cancer|August 21, 2025
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Filippo Branzanti, Massimiliano Bonifacio, et al.
British Journal of Haematology|July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsFrancesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
The Lancet. Haematology|February 7, 2017
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther N Oliva, Caterina Alati, Valeria Santini, et al.
Annals of Hematology|December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinibMassimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Cancer|February 13, 2026
Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosisFrancesca Palandri, Giovanni Caocci, Elisabetta Abruzzese, et al.
Cancer|April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosisFrancesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 10, 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' projectFrancesca Palandri, Giulia Benevolo, Alessandra Iurlo, et al.
Cancer|April 1, 2021
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcomeFrancesca Palandri, Mario Tiribelli, Massimo Breccia, et al.
Cancers|July 29, 2023
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET StudyFrancesca Palandri, Elena Rossi, Giuseppe Auteri, et al.
Pageof 12